KebedeHBegnaMD
Hematology • Rochester, MNHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Consultant Hematology Assistant Professor of Medicine
Dr. Begna is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 2003 - 2006
Westchester Medical CenterResidency, Internal Medicine, 1999 - 2003
Gondar College of Medical SciencesClass of 1989
Certifications & Licensure
MN State Medical License 2004 - 2025
FL State Medical License 2006 - 2009
NY State Medical License 2003 - 2005- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Publications & Presentations
PubMed
- 202 citationsGIPSS: genetically inspired prognostic scoring system for primary myelofibrosisAyalew Tefferi, Paola Guglielmelli, Maura Nicolosi, Francesco Mannelli, Mythri Mudireddy
Leukemia. 2018-03-23 - 89 citationsVenetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patientsErika Morsia, Kristen B. McCullough, Maansi Joshi, Joselle Cook, Hassan B. Alkhateeb
American Journal of Hematology. 2020-12-01 - 10 citationsVenetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxi...Omer Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, Kristen McCullough
American Journal of Hematology. 2024-02-01
Journal Articles
- Prognostic Impact of ASXL1 Mutations in Patients with Myelodysplastic Syndromes and Multilineage Dysplasia with or Without Ring SideroblastsAbhishek A Mangaonkar, Kebede H Begna, Leukemia Research
Abstracts/Posters
- Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be BeneficialKebede H. Begna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504...Kebede H. Begna, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- A Phase II of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (TAsigna) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µci/Kg/Dose2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Authored Content
- A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 TrialDecember 2022
- Prognostic Impact of ASXL1 Mutations in Patients with Myelodysplastic Syndromes and Multilineage Dysplasia with or Without Ring SideroblastsJuly 2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
